AiCuris Anti-infective Cures AG

General information

AiCuris Anti-infective Cures AG
Friedrich-Ebert-Str. 475
Building 302
42117 Wuppertal, North Rhine-Westphalia
Germany

Contact person: Alexander Birkmann, Vice President, BD
Company main phone: +49 (202) 317630
Company main fax: +49 (202) 317631177
Website: https://www.aicuris.com

Year founded:	2006
Source of foundation:	Spin-off from company
Name of foundation source:	Bayer Infection Research

Corporate description / mission:
AiCuris is a pharmaceutical company focused on the discovery, research and development of antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases.The company’s first product, Letermovir (Prevymis®) is a therapy for human cytomegalovirus (HCMV) infections. The company develops drugs for the treatment of viruses such as human CMV, herpes simplex virus (HSV), hepatitis B virus (HBV), and adenoviruses.

State of ownership: Private / independent
Headquarters: HQ: Yes

Remarks on ownership / listings
Formerly known as AiCuris Anti-infective Cures

Categorization

Sector:

Biotechnology - Therapeutics and Diagnostics

Subsector:

Anti-infectives
Nucleic acid drugs
Proteins
Small molecules

Primary therapeutic areas:

Infectious and parasitic diseases / infectiology / parasitology
Injury, poisoning and certain other consequences of external causes / toxicology
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified

Business model:

In-licensing
Out-licensing
R&D
Supplier / Distributor

Customer segments:

Consumers (mass market)
Hospitals
Large biotech & big pharma
Small biotech

Distribution:

Direct (own sales force)

Summary Products / Services / Technologies

Number of Biotech Products

Pre-clinical:	3
Phase I:	1
Phase III:	1
On the market:	2

Description of products:
Pritelivir (AIC316)
AIC468, etc.

Collaborations & Clients

Partnering strategy / collaborations:
MSD